文献速递糖尿病肥胖与代谢综合征

让现代糖尿病药物可负担可及:印度经验对其它国家的启示

Making Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries.
PubMed 文献 · Diabetes Care · 2026-09-16

本文分析印度通过仿制药竞争、价格监管、生产政策与公共分配举措降低SGLT2i、GLP-1 RA及胰岛素类似物价格的路径与成效,并讨论城乡可及性与仿制药质量差异等挑战,为高药价国家提供参考。

要点

  • 印度SGLT2i与GLP-1 RA专利到期后价格降约60%-90%,可及性显著提升。
  • 印度甘精胰岛素生物类似物成本远低于美国,跨国价差达15-65倍。
  • Ayushman Bharat等公共项目提升贫困人群可及性,但农村仍存障碍。

核心结论

  • 印度经验表明通过协调药品政策、监管效率与制造能力可实现现代糖尿病药物可负担可及。

研究设计与样本

  • 本文为政策分析类文章,梳理印度SGLT2i、GLP-1 RA及胰岛素类似物的价格趋势、监管框架、生产政策与公共分配举措。

主要发现

  • 印度SGLT2i与GLP-1 RA专利到期后价格降低约60%-90%,仿制药竞争、价格监管与政府支持推动可及性提升。
  • 印度甘精胰岛素生物类似物成本更低;部分药物印度仿制药价与美国标价相差15至65倍。
  • Ayushman Bharat等政府举措显著提升贫困与弱势人群可及性。
  • 农村地区现代疗法仍可能不可负担或不可获得,多厂家仿制药间质量与药代动力学可能存在差异。

临床怎么用

  • 对高药价国家,可借鉴印度以仿制药竞争、结构化价格监管与公共采购提升现代糖尿病药物可及性。
  • 关注农村与弱势人群的可及性缺口,并注意不同仿制药厂产品间质量与药代动力学差异。

局限性

  • 本文为政策分析而非临床试验,未提供患者结局的对照数据。
  • 印度经验向其他国家外推时需考虑各国监管、市场与卫生体系差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diabetes affects 589 million adults globally, 80% of whom live in low- and middle-income countries (LMICs). Although modern diabetes therapies such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes and analog insulins help reduce risk of hypoglycemia, affordability remains a barrier to equitable access to these agents. This article analyzes how India has reduced the costs of modern diabetes therapies and improved affordability, pricing trends, regulatory frameworks, pharmaceutical manufacturing policies, and public distribution initiatives in India. India has achieved approximately 60%-90% price reductions for SGLT2i and GLP-1 RA following patent expiry, driven by strong generic competition, structured price regulation, and governmental support, leading to much greater access to these agents. Costs of insulin biosimilars of glargine are also much lower in India, making them more affordable. Cross-national price comparisons show 15- to 65-fold differences between Indian generic prices and U.S. list prices for selected agents. On the policy front, government initiatives like the Ayushman Bharat have considerably helped to increase accessibility for the poor and vulnerable sections of the society. Despite these advances, challenges remain, particularly in rural areas where modern therapies may still be unaffordable or unavailable. Moreover, due to multiple manufacturers providing generics, there could be differences in quality and pharmacokinetics, even between the branded generics. However, India's experience demonstrates that affordable access to modern diabetes medicines is achievable through coordinated pharmaceutical policy, regulatory efficiency, and enhanced manufacturing capacity, offering lessons for LMICs and high-income countries facing high drug costs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mohan V, Sathweek RS, Anjana RM, et al. Making Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries. Diabetes Care. 2026. PMID: 42747945. doi:10.2337/dci26-0054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。